Cassandra Ashley, MD
Infectious Disease · Branson, MONPI 1649492927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 265 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,157 and has fallen 88.5% since, to $133 in 2025.
Across 265 payments — averaging $17.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$615
- Novo Nordisk$493
- Merck$437
- Abbott$403
- Insmed, Inc.$385
- AstraZeneca$378
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,43096%
- Education$2044%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 37 | $615 |
| Novo Nordisk | 31 | $493 |
| Merck | 28 | $437 |
| Abbott | 21 | $403 |
| Insmed, Inc. | 9 | $385 |
| AstraZeneca | 20 | $378 |
| Gilead | 15 | $300 |
| AbbVie(2 entities) | 17 | $298 |
| Boehringer Ingelheim | 17 | $251 |
| Amgen | 9 | $151 |
| Bayer | 15 | $148 |
| Pfizer | 8 | $128 |
| Dexcom, Inc. | 7 | $115 |
| Viiv Healthcare Company | 5 | $100 |
| Kowa Pharmaceuticals America, Inc. | 5 | $71 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Sanofi-aventis U.S. LLC | 5 | $65 |
| Johnson & Johnson | 3 | $50 |
| Radius Health, Inc. | 2 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Exact Sciences | 1 | $20 |
| Shield Therapeutics Inc | 1 | $20 |
How this compares
$4,634 in reported general payments places this provider in the 80th percentile of 177 infectious disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 86 | $119,107 |
| EliquisApixaban | 110 | $107,462 |
| JardianceEmpagliflozin | 79 | $88,402 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $43,029 |
| FarxigaDapagliflozin Propanediol | 34 | $39,884 |
| XareltoRivaroxaban | 45 | $37,886 |
| MounjaroTirzepatide | 34 | $37,015 |
| VraylarCariprazine Hcl | 21 | $30,366 |
| PrezcobixDarunavir/Cobicistat | 12 | $29,685 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $27,247 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $26,428 |
| CreonLipase/Protease/Amylase | 14 | $20,861 |
| TrulicityDulaglutide | 19 | $19,236 |
| VemlidyTenofovir Alafenamide | 12 | $17,395 |
| KerendiaFinerenone | 15 | $17,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $493 | $119,10786 claims |
| PfizerEliquis | $128 | $107,462110 claims |
| Boehringer IngelheimJardiance, Tradjenta | $251 | $101,53795 claims |
| Johnson & JohnsonXarelto, Prezcobix, Invokana | $50 | $77,16671 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $378 | $72,56491 claims |
| Lilly USA, LLCMounjaro, Trulicity | $615 | $56,25153 claims |
| AbbVieVraylar, Creon | $298 | $51,22735 claims |
| GileadDescovy, Vemlidy | $300 | $43,82224 claims |
| BayerKerendia | $148 | $17,20715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Branson
- Robert BelsheSaint Louis$382K
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Nirmol PhilipChesterfield$31K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Daniel HoftSt Louis$20K
- Matthew GermanChesterfield$16K
- Elvin GengSaint Louis$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.